To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.

1. To understand the severity and nature of participants experiences during rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, including their functional impact
2. To explore domains relevant to participants experiencing rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, and attitudes to domains identified from the literature

Inclusion Criteria

The criteria are:

• Patients aged 18 years and above
• English (conversational level) speaking, with the ability to give informed consent
• Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy

Exclusion Criteria

• Acutely life-threatening or worsening cancer
• Hearing impairment functionally limiting participation in verbal interview

MD Anderson Cancer Center